Literature DB >> 1713053

Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP.

D A Wolf1, P Schulz, F Fittler.   

Abstract

Experiments have been designed to investigate hormonal effects on the human prostatic carcinoma cell line LNCaP in the presence of complete foetal calf serum. At physiological concentrations (3.3 x 10(-9)M), several derivatives of 17 alpha-methyl-testosterone led to a significant reduction of cell proliferation, inhibition of colony formation in soft agar, change of morphology, induction of a prostate specific mRNA and down-regulation of c-myc RNA. Two different antiandrogens, hydroxyflutamide and cyproterone acetate, were capable of reversing the effects exerted by the synthetic androgens on growth properties. The proliferation rate of control cells devoid of androgen receptor was not inhibited by synthetic androgens. Our results indicate that the cellular androgen response mechanism of LNCaP cells is intact and that synthetic androgens elicit androgen receptor mediated suppression of the transformed phenotype. Rare cases of remission of prostatic cancer on androgen treatment have been reported. LNCaP cells may be a model of an uncommon class of prostatic cancer which responds favourably to androgen treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713053      PMCID: PMC1977337          DOI: 10.1038/bjc.1991.237

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  Tumor suppressor genes: the puzzle and the promise.

Authors:  R Sager
Journal:  Science       Date:  1989-12-15       Impact factor: 47.728

2.  Sequence of a cDNA clone encompassing the complete mature human prostate specific antigen (PSA) and an unspliced leader sequence.

Authors:  P Schulz; R Stucka; H Feldmann; G Combriato; H G Klobeck; F Fittler
Journal:  Nucleic Acids Res       Date:  1988-07-11       Impact factor: 16.971

3.  Negative controls of cell proliferation: human prostate cancer cells and androgens.

Authors:  C Sonnenschein; N Olea; M E Pasanen; A M Soto
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

4.  Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP.

Authors:  A L Schuurmans; J Bolt; E Mulder
Journal:  Prostate       Date:  1988       Impact factor: 4.104

5.  Experiences with F-32 in advanced carcinoma of the prostate.

Authors:  S H Corwin; M Malament; M Small; H D Strauss
Journal:  J Urol       Date:  1970-11       Impact factor: 7.450

6.  Genomic sequence of human prostate specific antigen (PSA).

Authors:  H G Klobeck; G Combriato; P Schulz; V Arbusow; F Fittler
Journal:  Nucleic Acids Res       Date:  1989-05-25       Impact factor: 16.971

7.  Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids.

Authors:  A L Schuurmans; J Bolt; M M Voorhorst; R A Blankenstein; E Mulder
Journal:  Int J Cancer       Date:  1988-12-15       Impact factor: 7.396

8.  Evaluation of the cytotoxic activity of diethylstilbestrol and its mono- and diphosphate towards prostatic carcinoma cells.

Authors:  P Schulz; H W Bauer; W P Brade; A Keller; F Fittler
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701

9.  Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP.

Authors:  E M Berns; W de Boer; E Mulder
Journal:  Prostate       Date:  1986       Impact factor: 4.104

10.  Aberrant c-myc RNAs of Burkitt's lymphoma cells have longer half-lives.

Authors:  D Eick; M Piechaczyk; B Henglein; J M Blanchard; B Traub; E Kofler; S Wiest; G M Lenoir; G W Bornkamm
Journal:  EMBO J       Date:  1985-12-30       Impact factor: 11.598

View more
  9 in total

1.  Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells.

Authors:  Mitchell G Lawrence; Naira V Margaryan; Daniela Loessner; Angus Collins; Kris M Kerr; Megan Turner; Elisabeth A Seftor; Carson R Stephens; John Lai; Lynne-Marie Postovit; Judith A Clements; Mary J C Hendrix
Journal:  Prostate       Date:  2011-01-12       Impact factor: 4.104

2.  Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC).

Authors:  John T Isaacs; W Nathaniel Brennen; Samuel R Denmeade
Journal:  Ann Transl Med       Date:  2019-12

3.  Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Prostate       Date:  2010-10-01       Impact factor: 4.104

4.  A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.

Authors:  Russell Szmulewitz; Supriya Mohile; Edwin Posadas; Rangesh Kunnavakkam; Theodore Karrison; Elizabeth Manchen; Walter M Stadler
Journal:  Eur Urol       Date:  2009-02-27       Impact factor: 20.096

5.  Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.

Authors:  A Maucher; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 6.  Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer.

Authors:  L B Barradell; D Faulds
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

7.  Sex Hormone Binding Globulin Modifies Testosterone Action and Metabolism in Prostate Cancer Cells.

Authors:  Huika Li; Thy Pham; Brett C McWhinney; Jacobus P Ungerer; Carel J Pretorius; Derek J Richard; Robin H Mortimer; Michael C d'Emden; Kerry Richard
Journal:  Int J Endocrinol       Date:  2016-11-20       Impact factor: 3.257

8.  Transcriptional down-regulation of c-myc in human prostate carcinoma cells by the synthetic androgen mibolerone.

Authors:  D A Wolf; F Kohlhuber; P Schulz; F Fittler; D Eick
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

9.  The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells.

Authors:  Lifang Lu; Holger Schulz; Dieter A Wolf
Journal:  BMC Cell Biol       Date:  2002-08-20       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.